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sonnel and patient time. Assessments at a single time point may
under- or overestimate the time required to perform related
activities. In this study, we use data from a large clinical trial of
exercise therapy in patients with heart failure to evaluate whether
there is evidence of a learning curve with regard to time spent on
non-exercise activities across 36 supervised exercise training ses-
sions across 12 weeks. METHODS: As part of the economic
evaluation planned alongside the NIH-sponsored HF-ACTION
trial, a Provider and Patient Time Assessment Survey was admin-
istered across 9 study sites representing a subset of 56 patients.
The survey was designed to assess provider time with and
without the patient, pre- and post-exercise, to account for a
variety of related tasks (e.g. pulling charts, patient education,
scheduling, etc.). Linear growth models were used to model the
trajectory change of time spent on ‘non-exercise’ activities across
36 visits. RESULTS: Data were available for 39 (69.6%) patients
who completed all 36 exercise sessions, 7 (12.5%) patients who
were still enrolled in ongoing exercise training, and 10 (17.9%)
patients who discontinued exercise training. The average non-
exercise time associated with supervised training was 30.3
(SD = 19.8) minutes, comprised of 20.6 minutes spent with
patients and 9.5 minutes without patients. After adjusting for
whether warm-up/cool-down activities were included, the total
time spent on non-exercise activities decreased signiﬁcantly
(parameter estimate: -1.04 minutes/week; p = 0.007), with
approximately equal reductions in time with patients (-0.57
minutes/week; p = 0.038), and without patients (-0.65 minutes/
week; p = 0.058) over 12 weeks. CONCLUSION: Our analysis
suggests that providers and patients experienced efﬁciency gains
in regard to time spent on activities associated with supervised
exercise training. These results demonstrate the potential impor-
tance of comprehensive time assessment when evaluating disease
management programs.
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OBJECTIVE: The goal of the study was to test the effects of
step therapy on pharmaceutical and medical utilization and
costs. This study examined the effect of step therapy for anti-
depressant and antihypertensive medications. METHODS: The
data was extracted from the MarketScan database, representing
the health care experience of enrollees in employer-sponsored,
commercial health plans. The sample consisted of employees
and dependents of 4 employers (2-step therapy and 2 controls)
who were continuously enrolled in the MarketScan database
from 2003 through the third quarter of 2006 and who used
antidepressants (N = 15,552 step therapy; N = 45,244 control)
or antihypertensives (N = 11,851 step therapy; N = 30,822
control) at least once during the study period. An analytic ﬁle
was created using a panel data framework, yielding 15 obser-
vations or quarters of data per patient. Chi-square and Stu-
dent’s t-tests were computed to compare demographic and
clinical characteristics as well as outcome variables between the
step therapy and comparison groups after step therapy had been
implemented for plans with step therapy. Multivariate general-
ized estimating equation (GEE) models were used to estimate
the effects of step therapy on spending and utilization while
controlling for important covariates and adjusting for clustering
by patient. RESULTS: Step therapy had the intended effect of
increasing generic prescribing and lowering brand prescribing.
Overall, medication costs were reduced in the step therapy plans
in the initial period following implementation. However, inpa-
tient, outpatient, and emergency room utilization and costs
were higher in the step therapy plans after step therapy was
implemented relative to the comparison groups. Medication
discontinuation rates for the targeted drugs increased in step
therapy plans. CONCLUSION: Implementation of step therapy
produces intended and unintended results. The intended results
of reducing drug costs are found to co-occur with unintended
results that may adversely affect patients as evidenced by higher
ER and inpatient utilization.
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OBJECTIVE: In this study, cost-effectiveness of different doses
of Atorvastatin, Pravastatin, Rosuvastatin and Simvastatin are
compared. The results are used to evaluate if prescription deci-
sions follow willingness to pay. METHODS: Incremental cost-
effectiveness ratios (ICERs) were calculated using a model to be
published in Value in Health. However, for this analysis, we used
efﬁcacy estimates from a meta-analysis that compared several
statins across dose ranges. Furthermore, we considered two sce-
narios. In scenario 1, doses are doubled after 12 weeks of treat-
ment if the LDL level is over 115 mg/dL; in scenario 2, the dose
is ﬁxed. For the analysis of prescription patterns and costs per
dose, we used ofﬁcial data. RESULTS: Results show that, in both
scenarios, Pravastatin 10 mg and 20 mg and Atorvastatin 10 mg
are dominated. Taking Simvastatin 10 mg as reference, the ICER
of Simvastatin 20 mg in scenario 1 is €203,780 and the ICER of
Rosuvastatin 10 mg is €108,293, while the ICER of Rosuvastatin
10 mg compared to Simvastatin 20 mg is €61,670. In scenario 2,
the ICERs of Simvastatin 20 mg and Rosuvastatin 10 mg are
€199.933 and €61.238, respectively, while Rosuvastatin 10 mg
dominates Simvastatin 20 mg. In both cases the Simvastatin
20 mg ICER is well above the €50.000 per life year gained
threshold. However, Simvastatin 20 mg is the most prescribed
alternative in Portugal. In fact, during 2006 its market share was
around 66%, while Simvastatin 10 mg accounted just for 2%
and Rosuvastatin 10 mg for 12%. Future research will show how
results change with the market launch of Rosuvastatin 5 mg.
CONCLUSION: Doctors are not inﬂuenced by economic evalu-
ation when prescribing statins. Results show that Simvastatin
10 mg should be used as ﬁrst line and Rosuvastatin 10 mg as
second line strategies. Most probably, the high market share of
Simvastatin 20 mg reﬂects the “ﬁrst mover” advantage in the
market.
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OBJECTIVE: To evaluate the effectiveness of a patient- and
physician-directed communication program to consider initia-
tion of statin therapy among diabetics. METHODS: Educa-
tional letters were sent to physicians and patients from a large
commercial health plan. Physician- and patient-directed letters
were sent to 593 and 579 patients respectively. Letters to the
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physicians were sent prior to the patient letters. Diabetic
patients absent of statin treatment in a prior 120-day period
were identiﬁed. Continuous eligibility was required for the
evaluation and only patients over 17 years of age were
included. Patients were observed for adding a statin during a
120-day follow-up period. Controls were identiﬁed from four
other plans with similar characteristics. One-to-one case-
control matching and t-test were performed to evaluate the
effect of the interventions. Regression analyses were performed
to determine the predictors of intervention responsiveness.
RESULTS: Mean age for patients in the program was approxi-
mately 55 years. There were 760 unique patients in both the
patient and physician intervention components. Overall, 170
(22.4%) and 112 (11.0%) patients added a statin in the case
versus control group (difference 11.4%, p < 0.0001). Speciﬁ-
cally, among the physician intervention component there were
17.8% and 11.6% of cases versus controls who added a statin
(difference = 6.22%, p < 0.05). Among the patient intervention
component there were 12.3% and 8.6% cases versus controls
who added a statin (difference 3.84%, p < 0.05). Signiﬁcant
positive predictors of adding a statin include presence of car-
diovascular disease, females, and higher comorbidities. CON-
CLUSION: Educational letter-based programs that are directed
to physicians and patients are effective in promoting the use of
statin therapy among diabetics.
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OBJECTIVE: To examine patients’ level of cardiovascular risk
in community based clinical practice and assess whether treat-
ment targets as speciﬁed in Canadian clinical guidelines
(hypertension—2007, dyslipidemia—2006, diabetes—2003,
metabolic syndrome—2006) are met. METHODS: A conve-
nience sample of more than 375 general practitioners recruited
from across Canada participated between September and Decem-
ber 2007. Case report forms were completed for at least 20
patients during normally scheduled ofﬁce visits. Current survey
results were compared to a similar survey of 450 general practi-
tioners and 17,188 patients conducted in January to April 2006
that used the 2003 dyslipidemia, 2003 diabetes, & 2005 hyper-
tension guideline targets to assess whether treatment targets were
met. RESULTS: A total of 1722 patients analyzed to date of
which 98% were taking lipid-lowering drugs. Approximately
14,000 patients’ data will be available upon study completion.
Demographics: 57% male, 40% 65 years or older, 53% 45–64
years. CV risk factors identiﬁed: 68% hypertension, 38% diabe-
tes, 26% family history premature CAD, 24% previous history
of MI, stroke, or PAD, 25% current or recent smoker, 9%
evidence of hyperdyslipidemia. Fifty-four percent of cohort had
three or more risk factors. Physician assessed CV risk level: 59%
high, 24% moderate, 18% low. Forty percent of patients met the
criteria for metabolic syndrome. Patients NOT at guideline
targets 2007 survey vs. 2006 survey: hypertension 22% vs. 26%,
LDL-C 47% vs. 34%, TC : HDL-C 35% vs. 31%, triglycerides
42% vs. 51%, FBG > 6.2 mmol. 34% vs. 44%, waist circumfer-
ence 55% vs. 55%. CONCLUSION: Preliminary aggregate data
shows that despite drug treatment many patients are still not at
lipid or blood pressure target levels. Community practice physi-
cians in this survey prescribe lipid-lowering drugs to predomi-
nantly high (59%) and moderate (24%) CV risk patients.
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OBJECTIVE: The environment of caring for acute stroke
patients impacts the outcome of the process. The aim of the study
was to explore the present institutional conditions of acute stroke
units and to compare these to the Hungarian national standards.
METHODS: A cross sectional study design was used to explore
the present conditions for acute stroke nursing (nurse stafﬁng,
skill mix, shift patterns, physical environment, etc.) in 11 insti-
tutions representing all regions of Hungary. The collected data
were compared to the professional standards lied in the govern-
ment decree. The data were collected in the beginning of 2005.
The data analysis was done with Chi-square and ANOVA
method using SPSS 11.0. RESULTS: The examined institutions
represent 19% (658) of active neurological beds in Hungary. The
nursing posts were not ﬁlled in 13% of the 11 units, furthermore
the total number of nursing posts were under the minimum
recommended standards with 17%. A total of 81% (219) of the
ﬁlled nursing posts are staffed with qualiﬁed registered nurses,
out of them 5% has a degree. In three institutions degree nurses
are not available at al. 80% of the nurses are between 21–45
years. The average nurse-patient ratio: 2.4:1 (lowest: 1.8, the
more: 3.6). In 10 out of 11 institutions have ISO 9001 QA
accreditation. The tools for helping nurses’ work are not enough
and correlating with lower qualiﬁcation levels signiﬁcantly
(p < 0.01). CONCLUSION: The nursing shortage is a serious
problem in stroke units (30%). Therefore, nursing can not meet
the criteria lied in the government decree and in the ISO 9001
system. Although the majority of the nursing staff are qualiﬁed
not all department employs degree nurses who could develop the
professional nursing.
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OBJECTIVE: To examine the relationship between the excessive
cost and quality of care across US hospitals for Medicare patients
undergoing lower extremity by pass surgery. METHODS: We
examined outlier payments in patients undergoing lower extrem-
ity bypass surgery (n = 43,886) using National Medicare claims
database. Using multiple logistic regression we explored the rela-
tionship between hospital outlier payments and hospital quality
as reﬂected by risk-adjusted mortality rates. RESULTS: The pro-
portion of patient associated with outlier payments was 10%.
Total Medicare outlier payments for lower-extremity bypass
graft was $78,921,669 averaging $18,214 per patient. There was
a negative correlation between risk-adjusted mortality rates and
outlier payments. Proportion of systematic variation in hospital
outlier payment rates explained by hospital factors explained
7.8% of in-between variation of outlier rates in lower extremity
bypass. CONCLUSION: There exist negative relationship
between quality and excessive cost across the hospitals. However,
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